TransCure bioServices Raises €2,5M Funding

New financing round will enable the company to accelerate its growth
and expand its international services offer

ARCHAMPS, France–(BUSINESS WIRE)–TransCure
bioServices (France), a one-stop-shop preclinical services
company dedicated to in-vivo full human immune system mouse
models, today announced that it has completed a 2.5 million euros
funding with Financière Arbevel (France). This financing round will
enable the company, healthy and profitable for the last three years, to
accelerate its international sales growth as well as to expand in
vivo preclinical pharmacology services offers into new product lines.

This financing was entirely subscribed by Arbevel Life Sciences
Crossover I, a european private equity fund based in Paris (France) with
a cross-over approach. TransCure bioServices will use the proceeds to
expand its profitable business activities in Europe and the USA, and to
develop additional platforms for international pharmaceutical and
biotech companies.

Marc Le Bozec, Managing Director of Arbevel Life Sciences
Crossover I Fund, will now join the Supervisory Board of the company and
commented: “We are excited to collaborate with TransCure bioServices’
management in expediting its growth by addressing new markets and
strengthening its commercial team”.

Patrick Nef, Chief Executive Officer and co-founder of TransCure
bioServices, commented: “We welcome Arbevel as a new shareholder to
boost our healthy and profitable international CRO business which
generated significant growth over the past 3 years. In addition to the
ongoing full human immune system mouse models for immuno-oncology,
inflammation, and infectious diseases we are excited to develop new
hu-liver and 100% human monoclonal antibody services. We look forward to
the contribution of Marc Le Bozec in the Supervisory Committee and to
benefit from his expertise of preclinical CRO business and financial
markets.”

“Arbevel’s investment underlines a steppingstone for the growth of our
worldwide business,” says Stéphane Legastelois, Chairman of
TransCure bioServices. “It allows TransCure bioServices to widen its
range of services and to investigate new exciting areas in the field of
full human antibodies.”

Agile Capital Markets acted as financial advisor for TransCure
bioServices in this transaction.

About TransCure
bioServices SAS.

TransCure bioServices SAS is a European CRO based in France offering
pre-clinical in vivo pharmacology fee-for-services to
international pharmaceutical, biotech and academic customers. Uniquely
designed full human immune system and hu-liver mouse models provide
predictive power for drug profiling and smarter drug candidate selection
for immuno-oncology, inflammation (IBD, SLE, MS, RA), auto-immune,
infectious (HIV), liver diseases, and vaccines. If you are looking for
check point inhibition, CART-cell designs, 100% IgG mAb, any drug
profiling involving the human immune system or hu-liver, contact us at www.tcbioservices.com

About Financière Arbevel

Founded in 1997, Financière Arbevel, an entrepreneurial investment
management company, has grown significantly since its takeover by the
current owners in early 2009 – the AUM progressed from EUR 25m to EUR
1.6bn as of today (of which EUR 732m under the umbrella SICAV “Pluvalca”
comprising 9 sub-funds). The company currently employs a total of 34
staff, of which 13 are dedicated to fund management/investment research.
Financière Arbevel is recognized for its expertise within the small &
mid cap asset class. We are a research-driven organization with a strong
emphasis on fundamental financial and strategic analysis, close
relationships with top managements of listed companies (more than 1000
company meetings last year) and a permanent quest for new investment
themes offering structural growth opportunities. The digitalization,
fintech, Industry 4.0, or the ageing of the world population are some of
our favorite investment themes. We ensure we 3/3 are following closely
the latest developments within this universe, by participating in
various conferences, trade fairs, sector-specific thematic events and by
meeting regularly with managements of listed companies. Our small & mid
cap DNA is spread across various strategies under the PLUVALCA family of
funds with a cross-asset approach comprising our core equity funds,
thematic equity funds, fixed income and diversified/flexible allocation
funds). In 2015, the Norwegian sovereign wealth fund chose Financière
Arbevel to manage its French equity mandate. In 2018, Financière Arbevel
pursued its development by launching its first European private equity
fund (FPCI form or “Professional private equity investment fund”) with a
cross-over approach focused on the non-listed life-science universe,
with the idea of accompanying a limited number of biotechnology
start-ups in their development. www.arbevel.com

Contacts

TransCure bioServices SAS
Patrick Nef, PhD
Chief
Executive Officer
Email: [email protected]